The diagnosis of pregnancy-associated cancer, although rare, is a condition of great human and social significance and difficult clinical management. A pregnancy-associated neoplasm is defined as a cancer diagnosis made during pregnancy or within 12 months after delivery/abortion. The most common cancers in pregnancy occur most frequently in women of reproductive age with an incidence overall like that observed in non-pregnant women of the same age. This incidence is likely to increase in view of both the expected increase in certain malignancies among young women (particularly breast cancer and melanoma) and the increasing frequency of pregnancies undertaken later in life (fourth and fifth decades of life) that is characterizing modern society. Chemotherapy is generally contraindicated before 12 weeks of pregnancy due to the increased risk of congenital anomalies while exposure in the second and third trimester of pregnancy to chemotherapy has been associated with more growth restriction and preterm delivery. Clinical decisions about the optimal management should consider maternal and fetal characteristics with the involvement of a multidisciplinary team.

Romano, A., Mastrangelo, S., Attina', G., Maurizi, P., Ruggiero, A., Pregnancy-associated Cancer and Chemotherapy during Pregnancy, <<BIOMEDICAL & PHARMACOLOGY JOURNAL>>, 2023; 16 (2): 705-714. [doi:10.13005/bpj/2652] [https://hdl.handle.net/10807/297721]

Pregnancy-associated Cancer and Chemotherapy during Pregnancy

Mastrangelo, Stefano;Attina', Giorgio;Maurizi, Palma;Ruggiero, Antonio
2023

Abstract

The diagnosis of pregnancy-associated cancer, although rare, is a condition of great human and social significance and difficult clinical management. A pregnancy-associated neoplasm is defined as a cancer diagnosis made during pregnancy or within 12 months after delivery/abortion. The most common cancers in pregnancy occur most frequently in women of reproductive age with an incidence overall like that observed in non-pregnant women of the same age. This incidence is likely to increase in view of both the expected increase in certain malignancies among young women (particularly breast cancer and melanoma) and the increasing frequency of pregnancies undertaken later in life (fourth and fifth decades of life) that is characterizing modern society. Chemotherapy is generally contraindicated before 12 weeks of pregnancy due to the increased risk of congenital anomalies while exposure in the second and third trimester of pregnancy to chemotherapy has been associated with more growth restriction and preterm delivery. Clinical decisions about the optimal management should consider maternal and fetal characteristics with the involvement of a multidisciplinary team.
2023
Inglese
Romano, A., Mastrangelo, S., Attina', G., Maurizi, P., Ruggiero, A., Pregnancy-associated Cancer and Chemotherapy during Pregnancy, <<BIOMEDICAL & PHARMACOLOGY JOURNAL>>, 2023; 16 (2): 705-714. [doi:10.13005/bpj/2652] [https://hdl.handle.net/10807/297721]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/297721
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact